Blood tests that look for signals associated with multiple cancers are attracting attention because a single sample may eventually help identify cancers that do not have established routine screening tests. Artificial intelligence (AI) and computational methods may help researchers analyze complex molecular patterns, including signals in cell-free DNA. But can AI detect cancer earlier using a blood test—and has research proved that these tests improve outcomes?
The evidence is promising in some respects, but the answer is not a simple yes. Studies show that multi-cancer early detection (MCED) tests can identify cancer-associated signals in some people without symptoms. They also show important limits: some cancers are missed, positive results require follow-up investigations, and researchers still need stronger evidence that screening with these tests improves health outcomes.
A key distinction matters throughout this article: a study of a blood-based cancer test does not automatically prove that AI itself caused the test’s performance, nor does it establish that every AI cancer-detection tool works in the same way.
How can a blood test look for several cancers?
Traditional cancer screening is generally designed for particular cancers, such as breast, cervical, or colorectal cancer. Multi-cancer early detection tests take a different approach. Depending on the test, they analyze biological signals in blood that may be associated with cancer, including patterns in cell-free DNA (cfDNA).
Cell-free DNA consists of small DNA fragments circulating outside cells. Some fragments originate from normal tissues, while others may reflect tumors or other biological processes. Circulating tumor DNA (ctDNA) is the portion of cell-free DNA that originates from a tumor. Researchers investigate molecular features such as DNA methylation patterns to look for signals that may be associated with cancer and, in some systems, estimate where the signal originated.
Computational models can help interpret large and complex datasets. Machine learning may be used in the development of some tests to recognize patterns that are difficult to assess using a single marker. However, test designs differ, and not every blood-based cancer test should be described as an AI test without evidence about the specific technology.
The National Cancer Institute’s overview of cancer screening tests explains that the effectiveness of multi-cancer detection tests in people without symptoms remains uncertain and needs evaluation in randomized clinical trials.
What did the PATHFINDER study find?
A prospective study published in The Lancet in 2023 evaluated a blood-based multi-cancer early detection test in adults aged 50 and older who did not have signs or symptoms of cancer.
Among 6,621 participants with analyzable results, the test reported a cancer signal in 92 people. A cancer diagnosis was confirmed in 35 of those participants, while 57 did not receive a cancer diagnosis during the study’s diagnostic evaluation. The researchers concluded that the study supported the feasibility of this approach but emphasized the need for further research into its clinical utility.
Read the original paper: Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.
These findings illustrate why a positive signal is not the same as a confirmed diagnosis. A person with a positive result may need additional blood tests, imaging, specialist appointments, or other procedures to determine whether cancer is present. Follow-up can create anxiety, cost, and medical risk, even when no cancer is ultimately found.
What does the larger PATHFINDER 2 study add in 2026?
A larger prospective study, PATHFINDER 2, was published in Nature Medicine on September 22, 2026. It evaluated the performance and safety of a blood-based MCED test in adults aged 50 or older without clinical suspicion of cancer.
Of 32,007 participants included in the performance analysis, the study reported:
- Cancer detection rate: 0.54%.
- Positive predictive value: 60.3% among participants with a positive test result.
- Specificity: 99.64%.
- Episode sensitivity across all cancers: 39.3% during the 12-month assessment period.
- Episode sensitivity in a prespecified 12-cancer subgroup: 69.8%.
The study also reported that 213 participants in the safety analysis underwent one or more invasive procedures after a positive test, and most of those procedures were nonsurgical. The researchers reported no serious study-related adverse events by the time of the analysis.
These numbers need context. The positive predictive value describes how often a positive result corresponded to a cancer diagnosis in the studied population. Specificity describes how often the test correctly returned a negative result for participants without the relevant cancer outcome. Sensitivity describes how often the test detected cancers that were present under the study’s definitions and follow-up period.
The 39.3% sensitivity result across all cancers means that a substantial proportion of cancers were not detected by the test during the assessment period. A high specificity figure does not cancel out that limitation. Performance also differed by cancer type, and the results should not be generalized to every blood test, AI system, or patient population.
Importantly, PATHFINDER 2’s reported endpoints were descriptive; the study did not use formal hypothesis testing to establish clinical benefit. Its authors stated that randomized trials and longer follow-up are needed to determine clinical utility.
Does this prove AI can detect cancer earlier?
Not on its own. PATHFINDER and PATHFINDER 2 evaluate a particular blood-based multi-cancer detection approach. Their results provide evidence about that test’s performance and the diagnostic work that can follow a positive result. They do not prove that AI independently improves outcomes, that every AI-enabled test has similar performance, or that adding this kind of test to routine screening reduces cancer deaths.
To establish the value of AI in cancer detection, researchers need to answer several separate questions:
- Can the model detect a signal? A model may distinguish patterns in a dataset, but this is only an initial technical result.
- Does it work in real screening populations? Performance must be assessed prospectively in people who may have no symptoms and a relatively low chance of having cancer.
- Can it identify cancer reliably without missing too many cases? Sensitivity varies across cancer types and stages, and false-negative results can provide false reassurance.
- Does earlier detection improve outcomes? Detecting a cancer earlier on a timeline does not automatically prove that screening prevents deaths or improves quality of life.
- Do benefits outweigh harms? Unnecessary follow-up tests, incidental findings, anxiety, costs, and overdiagnosis must be considered alongside potential benefits.
These are different measures of success. A promising accuracy result is not a substitute for evidence that using the test helps patients.
False positives and false negatives: why both matter
A false-positive result occurs when a test signals a possible cancer but the subsequent assessment does not confirm cancer. In the original PATHFINDER study, 57 of the 92 participants with a detected cancer signal did not receive a cancer diagnosis during the study’s diagnostic evaluation. That is a reminder that a positive screening result may begin a process rather than provide a definitive answer.
A false-negative result occurs when a test does not identify a cancer that is present. This is especially important when people interpret a negative blood test as proof that they do not have cancer. PATHFINDER 2’s reported sensitivity across all cancers was 39.3% during the 12-month assessment period, illustrating that a negative result cannot rule out every cancer.
For that reason, a multi-cancer blood test should not be treated as a replacement for recommended screening, diagnostic assessment of symptoms, or advice from a qualified healthcare professional. People with concerning symptoms should seek medical assessment even if a blood test or AI tool gives a reassuring answer.
Our guide on what AI can and cannot tell you about your symptoms explains the broader difference between AI-generated information and a medical diagnosis.
What about liquid biopsy and circulating tumor DNA?
Liquid biopsy is a broad term for analyzing tumor-related material in body fluids, most often blood. Depending on the clinical question, these tests may be investigated for detecting molecular changes, characterizing a known cancer, monitoring treatment, or identifying signs of recurrence.
Those uses should not be confused with screening people who have no symptoms. A test developed to monitor a patient with a known cancer may have a different purpose, evidence base, and performance profile from a test intended to screen a generally healthy population.
Similarly, cfDNA and ctDNA are not interchangeable terms. cfDNA includes DNA fragments from different sources, while ctDNA refers to the tumor-derived fraction. The biological signals, laboratory methods, and computational approaches used in a test all affect how results should be interpreted.
For related context, read our article on how AI could improve blood biomarker analysis and disease monitoring. That review covers broader research into circulating biomarkers and emphasizes why clinical validation is essential.
What evidence is still needed?
Before multi-cancer early detection tests can be considered a proven addition to routine screening, researchers need more than encouraging performance statistics from a prospective cohort. Important evidence includes:
- Randomized controlled trials comparing relevant screening strategies and measuring meaningful health outcomes.
- Longer follow-up to assess cancers missed at the initial test, later diagnoses, and possible effects on mortality.
- Evidence across diverse populations to determine whether performance varies by age, sex, ethnicity, risk factors, or healthcare setting.
- Clear follow-up pathways so that people with a positive result receive appropriate diagnostic assessment without unnecessary procedures.
- Cost-effectiveness analysis that considers the test, follow-up investigations, and potential downstream consequences.
- Independent evaluation of the test’s performance and of any AI or machine-learning component used in its development.
The PATHFINDER 2 publication specifically calls for randomized trials and longer follow-up to evaluate clinical utility. That qualification is central to interpreting the results accurately.
Is an AI blood test a replacement for standard cancer screening?
No. Evidence for established screening methods differs by cancer type and by the population being screened. A multi-cancer blood test should not be assumed to replace recommended screening procedures simply because it can look for signals associated with several cancers in one sample.
People should follow applicable screening guidance and discuss individual risk factors with their healthcare professional. A blood test result—positive or negative—must be interpreted in context, and symptoms that require evaluation should not be ignored because a screening test was negative.
For more general guidance, see our article on whether you should trust AI for health questions. AI tools can help explain research, but they should not be used as a substitute for diagnosis or personalized medical advice.
Frequently asked questions
Can AI detect cancer from a blood test?
AI and computational methods may help analyze molecular patterns in some blood-based tests. Research shows that certain multi-cancer detection tests can identify cancer-associated signals in some people without symptoms. However, the performance and clinical value of each test must be evaluated separately, and current evidence does not establish that all AI blood tests reliably detect cancer early.
How accurate are multi-cancer early detection tests?
There is no single accuracy figure that applies to all such tests. In PATHFINDER 2, published in 2026, reported specificity was 99.64%, positive predictive value was 60.3%, and sensitivity across all cancers was 39.3% during the 12-month assessment period. These measures describe different aspects of performance and should be interpreted together.
Can a negative blood test rule out cancer?
No. A negative result does not rule out every cancer. Sensitivity varies by cancer type and stage, and some cancers may not produce a detectable signal. Recommended screening and evaluation of symptoms remain important.
Do these tests prove that screening saves lives?
Not yet. PATHFINDER 2 provides evidence about test performance and safety, but its authors state that randomized trials and longer follow-up are needed to assess clinical utility. Detecting a signal is not the same as proving that screening reduces mortality or improves quality of life.
What is the difference between cfDNA and ctDNA?
Cell-free DNA (cfDNA) refers to DNA fragments circulating outside cells. Circulating tumor DNA (ctDNA) is the portion derived from a tumor. Researchers study these fragments for different purposes, but their interpretation depends on the test and clinical setting.
Conclusion
Blood-based multi-cancer detection is an important area of medical research, and computational methods may help interpret the complex biological signals these tests measure. The PATHFINDER studies show that a blood test can identify cancer-associated signals in some people without symptoms, while also revealing limits such as missed cancers and the need for diagnostic follow-up.
The evidence available in October 2026 does not justify claiming that AI blood tests have been proven to detect all cancers early or to improve survival. The next step is to establish clinical utility through randomized trials, longer follow-up, and careful evaluation of benefits and harms.
The most reliable takeaway is that AI-assisted blood analysis is a promising research direction—not a replacement for established screening guidance or professional medical assessment.
Sources
- Schrag D, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. The Lancet. 2023.
- Nabavizadeh N, et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nature Medicine. Published September 22, 2026.
- National Cancer Institute. What Cancer Screening Tests Check for Cancer?.
- National Institutes of Health, PubMed Central. PATHFINDER: A Prospective Cohort Study of Blood-Based Multi-cancer Early Detection.